Nattokinase for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Nattokinase for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A clot-dissolving enzyme from fermented soybeans, taken as a capsule. Short trials show clotting times lengthen and blood pressure falls modestly where readings are already high. The one long, independently funded trial found none of it. Slower clotting is the main hazard, especially alongside blood thinners. Short-term biology is real; the long-term artery payoff is unproven. (Full Review)

Protocol

Standard dose
2,000 FU once daily
Equivalent to 100 mg of extract standardised to 20,000 FU/g; the ceiling authorised in the European Union for supplement use.
Best time of day
Away from food, before bed
An empty stomach limits proteolytic degradation, and evening dosing places peak serum activity, around 13 hours later, across the morning hours when clotting activity peaks.
Higher-dose approach
4,000–8,000 FU daily
Appears in the plaque and cognition trials; no demonstrated advantage on blood pressure and widens the bleeding margin.
Time to effect
Blood pressure
8 weeks
Blood-pressure change, where it occurs, takes the full 8 weeks used in the trials, so judging the supplement earlier is premature.
Clotting markers
Within hours
Coagulation markers shift within hours of the first dose; single-dose effects run roughly 2–8 hours.
Post-stroke recovery
60 days
Disability-scale improvement added to standard rehabilitation in the weeks after an ischaemic stroke.

Benefits

Contraindications
  • Warfarin or another vitamin K antagonist, a direct oral anticoagulant, heparins, thrombolytics, or dual antiplatelet therapy
  • Active peptic ulcer disease, oesophageal varices, or gastrointestinal bleeding within 12 months
  • Documented cerebral microbleeds, cerebral amyloid angiopathy, or haemorrhagic stroke at any time
  • Ischaemic stroke or myocardial infarction within 90 days
  • Platelet count below 100 × 10⁹/L, haemophilia, von Willebrand disease, or other inherited bleeding disorder
  • Child-Pugh Class B or C liver disease
  • Soy allergy, prior natto reaction, or prior reaction to a Bacillus-fermented product
  • Pregnancy, breastfeeding, and anyone under 18
  • Within 14 days before, or 7 days after, any surgical or dental procedure
    •
Key Interactions
  • Antiplatelet agents (aspirin, clopidogrel, ticagrelor, prasugrel, dipyridamole)
  • NSAIDs (ibuprofen, naproxen, diclofenac, high-dose aspirin)
  • SSRIs and SNRIs (sertraline, fluoxetine, venlafaxine)
  • Antihypertensives (lisinopril, losartan, amlodipine, hydrochlorothiazide)
  • Blood-pressure-lowering supplements (beetroot nitrate, potassium, magnesium, garlic, hibiscus, taurine)
  • Bleeding-risk supplements (fish oil, Ginkgo biloba, high-dose vitamin E, curcumin, bromelain, serrapeptase, lumbrokinase)
  • Red yeast rice and statins
  • Vitamin K2 supplements (menaquinone-4, menaquinone-7)
    •

Risk & Side Effects

  • High: Increased bleeding tendency and potentiation of antithrombotic drugs
    •
  • Medium: Small rise in fasting blood glucose
    •
  • Low: Unfavourable lipid shifts at lower total doses; allergic reactions, including anaphylaxis; loss of warfarin control from residual vitamin K2; gastrointestinal upset and histamine-related symptoms
    •
  • Speculative: Viable Bacillus subtilis exposure in immunocompromised users
    •

Monitoring

Marker Target Why
Home blood pressure <120/75 mmHg The one benefit with replicated trial support
Platelet count 175–350 × 10⁹/L Defines the margin before slower clotting becomes bleeding
PT/INR 0.9–1.1 Detects drift in the clotting cascade
aPTT 25–33 s The measure most consistently prolonged by nattokinase
D-dimer <0.25 mg/L FEU Tracks fibrin turnover, which should rise on treatment
Fibrinogen 200–300 mg/dL High values mark the clot-prone physiology the enzyme targets
High-sensitivity C-reactive protein <1.0 mg/L Inflammation context for clot-prone physiology
Fasting glucose 75–86 mg/dL Pooled trials show a small upward drift on treatment
HbA1c <5.4% Confirms whether any glucose drift is real or noise
Non-HDL cholesterol <100 mg/dL Low-dose trials showed unfavourable lipid shifts
Carotid intima-media thickness and plaque area No established target for this intervention; track change from own baseline The endpoint where the trials disagree most sharply
Lipoprotein(a) <30 mg/dL (<75 nmol/L) Identifies inherited clot-prone risk the enzyme does not address

Cadence: Home blood pressure twice daily for the first 4 weeks, then weekly; coagulation panel and lipids repeated at 8 weeks; then the full panel every 6–12 months, or every 3 months for anyone over 65 or on any agent affecting platelets. Any bleeding symptom triggers immediate retesting rather than waiting for the scheduled interval.

Qualitative Assessment

  • New or unexplained bruising, particularly on the trunk rather than the limbs
  • Gum bleeding when brushing, and nosebleeds lasting longer than 10 minutes
  • Bleeding from small cuts that takes noticeably longer to stop than before
  • Heavier or longer menstrual flow
  • Black or tarry stools, which warrant stopping immediately
  • Leg heaviness, swelling, or calf discomfort after long periods seated
  • Dizziness on standing, which suggests additive blood-pressure lowering
  • Bloating, loose stools, or nausea in the first two weeks
  • Flushing, itching, or headache after dosing, which may indicate a histamine response
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.